Come together to end ALS
The Young Faces of ALS (YFALS) campaign was created in 2009 by people living with ALS who received their ALS diagnosis before their 35th birthdays. YFALS became the first community for young people afflicted by ALS, as well as their families and friends, committed to raising awareness of ALS and funds for ALS research at the ALS Therapy Development Institute (ALS TDI).

YFALS' Impact on ALS Research

In 2011, the Young Faces of ALS founded the Corntoss Challenge and since then, the Young Faces of ALS have raised over $2 million for research at ALS TDI. Along with fundraising the YFALS Ambassadors, both people living with ALS and people whose lives were impacted by ALS at a young age, are huge advocates in the ALS community. You can read more about the YFALS Ambassadors here.
YFALS' Impact on ALS Research
YFALS and ALS TDI

YFALS and ALS TDI

YFALS supports ALS TDI, which was founded in 1999 by Jamie Heywood after his brother, Stephen Heywood, was diagnosed with ALS at age 29. After finding no treatment options for his brother, Jamie realized that a gap existed in the preclinical development of therapies for ALS. Jamie founded ALS TDI in the basement of his family’s Newton, MA home in an effort to bridge this gap and bring effective treatments to people with ALS as quickly as possible. Although Stephen is no longer with us, ALS TDI continues to fight for young people with ALS today.

Ambassador Spotlight

Osiel Mendoza

Osiel was diagnosed with ALS in October 2016 at age 21. In 2017, he created a video and campaign called #YolkUp4ALS, which raised funds for ALS TDI. To learn more about Osiel, check out his profile.

Osiel Mendoza
ALS TDI
ALS Therapy Development Institute
The ALS Therapy Development Institute (ALS TDI) and its researchers discover and develop potential treatments for ALS. It is the world's first and largest nonprofit biotech focused 100 percent on ALS research. Led by drug development experts and people with ALS, ALS TDI understands the urgent need to slow and stop this disease.
Based in Cambridge, MA, ALS TDI has more than 30 full-time, industry trained, drug development experts on staff. ALS TDI is internationally recognized as a leader in preclinical and translational ALS research, and partners with pharmaceutical companies and biotechs around the world. Rated a four-star nonprofit on Charity Navigator, ALS TDI spends 87 cents of every dollar raised on finding effective treatments and cures for ALS. Learn more at www.als.net.